Marine peptides in lymphoma: surgery at molecular level for therapeutic understanding

Salman Ahmed1, Michael Aschner2, Khalaf F Alsharif3

  • 1Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, 75270, Pakistan.

Insights

Marine peptides show promise as novel treatments for lymphoma, a common blood cancer. These compounds offer targeted anti-lymphoma effects with reduced toxicity, addressing limitations of conventional therapies.

Area of Science:

  • Marine biology
  • Cancer research
  • Pharmacology

Background:

  • Lymphoma is a prevalent blood cancer with significant mortality.
  • Conventional therapies face challenges like side effects, drug resistance, and relapse.
  • There is a critical need for novel and effective lymphoma treatments.

Purpose of the Study:

  • To review the molecular mechanisms of marine peptides against lymphoma.
  • To explore the potential of marine peptides as therapeutic agents for lymphoma.
  • To highlight advancements in marine peptide-derived antibody-drug conjugates (ADCs).

Main Methods:

  • Literature review of studies on marine peptides and their anti-lymphoma properties.
  • Analysis of molecular pathways targeted by marine peptides.
  • Examination of the role of marine peptide-derived ADCs.

Main Results:

  • Marine peptides exhibit diverse anti-lymphoma mechanisms, including apoptosis induction, cell cycle arrest, and immune modulation.
  • These peptides can disrupt cancer cell membranes and microtubule stability.
  • Marine peptide-derived ADCs show synergistic effects with other anti-lymphoma drugs.

Conclusions:

  • Marine peptides represent a promising source for developing novel anti-lymphoma therapies.
  • Understanding their molecular mechanisms can guide future drug development.
  • Further research into marine-derived compounds could lead to new lymphoma treatments.